Your browser is no longer supported. Please, upgrade your browser.
Settings
CRSP CRISPR Therapeutics AG daily Stock Chart
CRSP [NASD]
CRISPR Therapeutics AG
Index- P/E- EPS (ttm)-2.35 Insider Own0.50% Shs Outstand53.17M Perf Week-10.37%
Market Cap1.90B Forward P/E- EPS next Y-3.49 Insider Trans-2.74% Shs Float33.06M Perf Month-5.28%
Income-111.00M PEG- EPS next Q-0.77 Inst Own47.70% Short Float13.34% Perf Quarter-31.06%
Sales35.30M P/S53.79 EPS this Y18.10% Inst Trans31.15% Short Ratio4.44 Perf Half Y-39.82%
Book/sh8.81 P/B4.05 EPS next Y- ROA-30.90% Target Price66.69 Perf Year89.14%
Cash/sh9.16 P/C3.90 EPS next 5Y- ROE-40.40% 52W Range17.40 - 73.90 Perf YTD52.09%
Dividend- P/FCF- EPS past 5Y- ROI-32.00% 52W High-51.68% Beta-
Dividend %- Quick Ratio15.40 Sales past 5Y- Gross Margin- 52W Low105.24% ATR2.44
Employees127 Current Ratio15.40 Sales Q/Q-75.00% Oper. Margin- RSI (14)47.76 Volatility6.69% 6.92%
OptionableYes Debt/Eq0.00 EPS Q/Q-73.60% Profit Margin- Rel Volume0.70 Prev Close35.30
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume992.74K Price35.71
Recom2.40 SMA20-1.46% SMA50-2.09% SMA200-28.22% Volume695,629 Change1.16%
Nov-30-18Initiated Needham Buy $62
Oct-10-18Initiated Wells Fargo Outperform $65
Oct-10-18Initiated Guggenheim Neutral
Sep-21-18Initiated Raymond James Underperform
May-15-18Reiterated Chardan Capital Markets Buy $25 → $72.50
Apr-06-18Initiated Goldman Buy $86
Mar-08-18Initiated JMP Securities Mkt Outperform $69
Jan-23-18Upgrade SunTrust Hold → Buy
Dec-22-17Initiated Piper Jaffray Overweight
Jul-14-17Initiated SunTrust Hold $16
Mar-28-17Initiated Chardan Capital Markets Buy $23.50
Dec-10-18 04:31PM  Why CRSP Stock Has Added Layers of Risk InvestorPlace
12:54PM  Here's Why Crispr Therapeutics Rose 17% in November Motley Fool
12:42PM  Here's Why Editas Medicine Jumped 23% in November Motley Fool
Dec-01-18 11:24AM  Genetic editing is this week's champ Fed's Powell is the chump Yahoo Finance
Nov-30-18 05:45PM  CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know Zacks
04:14PM  This Biotech Stock Could Launch Its First CRISPR Drug In 2022 Investor's Business Daily
10:31AM  Why Crispr Therapeutics Stock Is Up By 65% So Far in 2018 Motley Fool
Nov-26-18 04:22PM  With genetically edited babies, a scientist transgresses a moral boundary MarketWatch
02:46PM  Mass. biotech leaders voice alarm over report of first gene-edited babies American City Business Journals
Nov-21-18 07:00AM  CRISPR Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire +7.12%
Nov-18-18 04:51PM  Better Buy: CRISPR Therapeutics AG vs. Sangamo Therapeutics Inc. Motley Fool
Nov-13-18 08:45AM  New Research Coverage Highlights CAS Medical, Saia, Core Laboratories N.V, Perceptron, CRISPR Therapeutics AG, and IEC Electronics Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-12-18 05:50PM  CRISPR Therapeutics AG (CRSP) Stock Moves -0.55%: What You Should Know Zacks
11:51AM  3 DNA Stocks That Are on the Uptrend InvestorPlace
Nov-09-18 07:00AM  CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology GlobeNewswire
Nov-07-18 07:46PM  Cambridge's Editas asks FDA to start gene editing trial American City Business Journals +10.81%
04:33PM  CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-05-18 02:13PM  Here's Why CRISPR Stocks Fell as Much as 40.7% in October Motley Fool
09:35AM  ImmunoGen (IMGN) Beats on Earnings in Q3, Lowers Guidance Zacks
07:55AM  5 Drug/Biotech Stocks Set to Trump Estimates in Q3 Earnings Zacks
Nov-02-18 11:31AM  VIVUS (VVUS) Q3 Loss Narrower Than Expected, Revenues Up Y/Y Zacks
09:15AM  Geron's (GERN) Q3 Earnings Beat, Revenues Miss, Shares Down Zacks
Nov-01-18 11:03AM  Ophthotech (OPHT) Q3 Earnings Beat, Gene Therapy in Focus Zacks +8.61%
Oct-31-18 11:23AM  Is a Beat in Store for Editas (EDIT) This Earnings Season? Zacks
Oct-30-18 09:48AM  Is a Beat in Store for CRISPR (CRSP) This Earnings Season? Zacks
Oct-29-18 01:44PM  Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q2 Zacks
Oct-26-18 03:41PM  3 Stocks to Buy and Hold for the Next 50 Years Motley Fool
Oct-24-18 08:23PM  Vertex Pharmaceuticals Inc (VRTX) Q3 2018 Earnings Conference Call Transcript Motley Fool -9.17%
Oct-22-18 12:08PM  Is a Beat in Store for Vertex (VRTX) This Earnings Season? Zacks
Oct-21-18 06:33AM  Better Buy: CRISPR Therapeutics AG vs. Intellia Therapeutics Inc. Motley Fool
Oct-14-18 02:34PM  Treating Genetic Diseases in Utero Could Change the CRISPR Space GuruFocus.com
Oct-12-18 02:23PM  3 High-Reward Stocks From 3 Emerging Trends InvestorPlace
12:48PM  FDA lifts hold on first-ever CRISPR/Cas9 gene-editing trial American City Business Journals
09:35AM  Company News For Oct 12, 2018 Zacks
Oct-11-18 05:16PM  Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts Zacks
01:50PM  Here's Why CRISPR Therapeutics Has Lost One-Third of Its Value Since September Motley Fool
08:49AM  Why CRISPR Therapeutics Stock Is Heading Higher Today Motley Fool
08:00AM  Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Myriad Genetics ACCESSWIRE
06:25AM  CRISPR Therapeutics Set to Surge After FDA Lifts Hold on Human Trial Investopedia
Oct-10-18 05:11PM  After-hours buzz: SQ, FLR & more CNBC
05:03PM  FDA lifts hold on first-ever CRISPR/Cas9 gene-editing trial American City Business Journals
04:12PM  Crispr stock up 8% as company says FDA accepted new-drug application MarketWatch
04:01PM  CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease GlobeNewswire
Oct-09-18 04:35PM  Better Buy: Crispr Therapeutics AG vs. Editas Motley Fool
04:19PM  FDA Sets Action Date for Recro's Pain Management Candidate Zacks
10:21AM  Bausch's Bryhali Gets Tentative FDA Nod for Plaque Psoriasis Zacks
Oct-05-18 07:05PM  Cramer's lightning round: Watch outmomentum stocks are o... CNBC Videos
03:13PM  Who Are The Top Investors In CRISPR Therapeutics AG (NASDAQ:CRSP)? Simply Wall St.
Oct-02-18 10:30AM  Global Stem Cell Market Expected to Reach $270.5 Billion ACCESSWIRE -6.19%
07:00AM  CRISPR Therapeutics to Present at the Chardan Genetic Medicines Conference GlobeNewswire
Sep-27-18 01:55PM  Guide to CRISPR Stocks & Latest Apple, Fed, GDP News | Free Lunch Zacks
Sep-21-18 04:32PM  Here's Why CRISPR Therapeutics AG Fell as Much as 10.8% Today Motley Fool -9.19%
Sep-20-18 08:33PM  CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares GlobeNewswire -5.59%
09:02AM  The Daily Biotech Pulse: Adverum Snags Fast Track Designation, Crispr To Offer Shares, Elanco Animal Health To Debut Benzinga
08:32AM  Dow Jones Futures: Tilray, Marijuana Stocks Still Buzzing; Red Hat, Crispr Move On News Investor's Business Daily
Sep-19-18 05:03PM  After-hours buzz: TLRY, RHT & more CNBC
04:37PM  Crispr stock down 5% after company plans secondary offer MarketWatch
04:08PM  CRISPR Therapeutics Announces Proposed Public Offering of Common Shares GlobeNewswire
10:30AM  Stem Cell Deals Moving the Markets ACCESSWIRE
Sep-17-18 08:00AM  CRISPR Therapeutics and ViaCyte Announce Strategic Collaboration to Develop Gene-Edited Stem Cell-Derived Therapy for Diabetes GlobeNewswire -9.10%
Sep-16-18 08:31AM  Is CRISPR Therapeutics AG a Buy? Motley Fool
Sep-10-18 04:30PM  CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology GlobeNewswire
01:52PM  U.S. appeals court upholds MIT, Harvard patents on CRISPR gene editing Reuters
Sep-07-18 08:18AM  Better Buy: Editas Medicine, Inc. vs. CRISPR Therapeutics Motley Fool
Sep-05-18 09:16AM  Forget CRISPR Therapeutics: Vertex Pharmaceuticals Incorporated Is a Better Biotech Stock Motley Fool
Sep-04-18 11:29AM  Here's Why CRISPR Stocks Rose as Much as 18.7% in August Motley Fool
08:00AM  Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Zogenix ACCESSWIRE
Sep-02-18 09:10AM  3 Biotech Stocks That Could Soar Next Week Motley Fool
Sep-01-18 07:03AM  About to Buy Penny Stocks? Look at These 3 Companies First Motley Fool
Aug-31-18 02:27PM  This Start-Up Thinks It Can Tackle One of CRISPR's Biggest Obstacles Motley Fool +6.00%
Aug-30-18 07:00AM  CRISPR Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Aug-27-18 01:12PM  Gene Editing is a Major Technology to Watch InvestorPlace
Aug-24-18 08:16AM  3 Relatively Safe Ways to Invest in Gene Editing Motley Fool
Aug-21-18 07:12AM  The Cost of Cures: How Investing in Biotech Stocks Could Soon Be Radically Changed Motley Fool +5.36%
Aug-09-18 10:00AM  Is Crispr Therapeutics Stock Grossly Overvalued? Motley Fool
07:44AM  Jim Cramer Advises His Viewers On Visa, Zuora And More Benzinga
Aug-08-18 06:59PM  Cramer's lightning round: If Zuora's stock dips, buy more CNBC Videos
Aug-07-18 05:01PM  CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2018 Financial Results GlobeNewswire
Aug-04-18 12:28PM  Here's Why CRISPR Therapeutics Lost 18.8% in July Motley Fool
Aug-03-18 01:38PM  [$$] CRISPR Technology Still Holds Big Promise Barrons.com
Jul-30-18 01:47PM  Here's Why Vertex Pharmaceuticals Earnings Are Growing Faster Than Revenue Motley Fool
Jul-28-18 09:03AM  Intellia Therapeutics, Inc. Stock History: The Story of a CRISPR Gene Editing Pioneer Motley Fool
Jul-27-18 10:19AM  3 Reasons Why Vertex Pharmaceuticals Stock Isn't Nearly as Expensive as It Looks Motley Fool -5.55%
Jul-26-18 02:34PM  Vertex Pharmaceuticals (VRTX) Q2 2018 Earnings Conference Call Transcript Motley Fool
Jul-25-18 08:00AM  Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Editas Medicine ACCESSWIRE
Jul-24-18 04:06PM  Here's Why CRISPR Stocks Are Down as Much as 11.4% Today Motley Fool -9.53%
07:55AM  Free Research Reports on CorMedix and Three More Biotech Stocks ACCESSWIRE
Jul-17-18 03:01PM  Yet Another CRISPR Worry: What Should Investors Do? Motley Fool
08:10AM  Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Tonix Pharmaceuticals ACCESSWIRE
Jul-16-18 07:31PM  [$$] New Research Prompts Selloff in Companies Using Crispr Technology The Wall Street Journal -8.60%
03:16PM  A Single Study Is No Reason to Sell Crispr Stock InvestorPlace
02:28PM  CRISPR gene editing can cause risky collateral DNA damage - study Reuters
01:05PM  CRISPR Therapeutics Stock History: The Rise of the World's Biggest Gene-Editing Biotech Motley Fool
12:21PM  Gene-editing stocks tumble on concerns about DNA damage MarketWatch
Jul-10-18 09:37AM  Here's Why CRISPR Stocks Have Gained as Much as 169% in 2018 (So Far) Motley Fool
Jul-09-18 01:26PM  Here's Why CRISPR Therapeutics AG Fell 14.7% in June Motley Fool
02:00AM  Abingworth Raises $315m for ABV VII 12th Life Sciences Fund PR Newswire
Jul-08-18 03:15PM  Why bluebird bio's Shares Have Tumbled 11.9% in 2018 So Far Motley Fool
Jul-06-18 09:03AM  Are Options Traders Betting on a Big Move in CRISPR Therapeutics (CRSP) Stock? Zacks
Jul-05-18 08:39AM  Nightstar Therapeutics (NITE) in Focus: Stock Moves 6.3% Higher Zacks
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient. The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; and with the ViaCyte, Inc. for designing allogeneic cell therapies derived from gene edited human stem cells for use in the treatment of diabetes type 1, diabetes type 2, and insulin dependent diabetes. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kulkarni SamarthChief Executive OfficerDec 07Option Exercise1.8121,50038,915167,290Dec 11 04:29 PM
CELGENE CORP /DE/10% OwnerNov 21Sale19.2580,0001,540,0004,173,019Dec 07 09:57 AM
CAGNONI PABLO JDirectorJul 05Option Exercise5.591,6849,4141,684Jul 05 06:25 PM
CAGNONI PABLO JDirectorJul 05Sale62.001,684104,4080Jul 05 06:25 PM
CAGNONI PABLO JDirectorJul 03Option Exercise5.595,81632,5115,816Jul 05 06:25 PM
CAGNONI PABLO JDirectorJul 03Sale62.005,816360,5920Jul 05 06:25 PM
EMSTER KURT VONDirectorJun 05Sale12.5192011,50918,316Jun 07 04:36 PM
Kulkarni SamarthChief Executive OfficerJun 01Option Exercise1.8115,00027,150163,560Jun 05 08:20 PM
Kulkarni SamarthChief Executive OfficerJun 01Sale69.3615,0001,040,400148,560Jun 05 08:20 PM
Novak RodgerPresidentMay 17Option Exercise8.2775,000620,4241,223,007May 21 04:54 PM
Novak RodgerPresidentMay 17Sale60.0075,0004,500,0001,148,007May 21 04:54 PM
Bolzon Bradley J PhDDirectorMay 15Sale57.9944,0002,551,440640,014May 17 05:15 PM
Woiwode ThomasDirectorMay 15Sale57.9944,0002,551,440640,014May 17 05:11 PM
EMSTER KURT VONDirectorMay 14Sale55.36400,00022,142,5561,237,202May 15 08:04 PM
EMSTER KURT VONDirectorMay 11Sale52.84250,00013,209,9001,637,202May 15 08:04 PM
Bolzon Bradley J PhDDirectorMay 08Sale50.549,241467,06734,745May 09 05:14 PM
Woiwode ThomasDirectorMay 08Sale51.451,65385,0475,629May 09 05:15 PM
Bolzon Bradley J PhDDirectorMay 07Sale50.38119,7096,030,82634,977May 09 05:14 PM
Woiwode ThomasDirectorMay 07Sale50.38119,7096,030,82634,977May 09 05:15 PM
Bolzon Bradley J PhDDirectorApr 30Sale50.2930,5661,537,13838,064May 02 06:00 PM
Woiwode ThomasDirectorApr 30Sale50.2930,5661,537,13838,064May 02 06:00 PM
Bolzon Bradley J PhDDirectorApr 27Sale50.0211,648582,65538,852Apr 30 08:58 PM
Woiwode ThomasDirectorApr 27Sale50.0211,648582,65538,852Apr 30 08:57 PM
Bolzon Bradley J PhDDirectorApr 26Sale50.11210,61010,553,78239,152Apr 30 08:58 PM
Woiwode ThomasDirectorApr 26Sale50.11210,61010,553,78239,152Apr 30 08:57 PM
Woiwode ThomasDirectorApr 24Sale50.9922,8411,164,65544,582Apr 26 05:01 PM
Bolzon Bradley J PhDDirectorApr 24Sale50.9922,8411,164,65544,582Apr 26 04:57 PM
Versant Venture Capital V, L.P10% OwnerApr 24Sale50.9922,8411,164,65544,582Apr 26 04:44 PM
Versant Venture Capital IV, L.10% OwnerApr 23Sale50.68101,9945,168,90145,171Apr 24 07:44 PM
Woiwode ThomasDirectorApr 23Sale50.68101,9945,168,90145,171Apr 24 07:42 PM
Bolzon Bradley J PhDDirectorApr 23Sale50.68101,9945,168,90145,171Apr 24 07:41 PM
Dylan-Hyde TylerChief Legal OfficerJan 16Option Exercise12.5721,000263,97045,094Jan 18 05:38 PM
Dylan-Hyde TylerChief Legal OfficerJan 16Sale28.0366,0001,850,25525,204Jan 18 05:38 PM
EMSTER KURT VONDirectorJan 05Buy22.7565,9341,499,9991,887,202Jan 11 09:00 PM
BAYER AKTIENGESELLSCHAFT10% OwnerJan 05Buy22.75527,47211,999,9885,632,802Jan 30 02:21 PM
EMSTER KURT VONDirectorJan 05Sale26.9692,3372,489,4061,821,268Jan 09 04:39 PM
Dylan-Hyde TylerChief Legal OfficerJan 02Option Exercise12.578,000100,56078,204Jan 04 07:14 PM
EMSTER KURT VONDirectorJan 02Sale26.7637,7541,010,1231,913,605Jan 04 05:29 PM
Dylan-Hyde TylerChief Legal OfficerJan 02Sale21.6438,000822,50070,204Jan 04 07:14 PM
Dylan-Hyde TylerChief Legal OfficerDec 29Option Exercise13.3315,300203,909124,274Jan 02 04:18 PM
Dylan-Hyde TylerChief Legal OfficerDec 29Sale22.7430,300689,055100,204Jan 02 04:18 PM
Dylan-Hyde TylerChief Legal OfficerDec 28Option Exercise14.4370010,101115,904Jan 02 04:18 PM
Dylan-Hyde TylerChief Legal OfficerDec 28Sale21.7570015,225115,204Jan 02 04:18 PM
Bolzon Bradley J PhDDirectorDec 22Sale20.3026,016528,23727,724Dec 27 04:17 PM
Dylan-Hyde TylerChief Legal OfficerDec 22Sale20.5515,000308,250115,204Dec 27 04:17 PM
Woiwode ThomasDirectorDec 22Sale20.293,05962,0704,959Dec 27 04:14 PM
Kulkarni SamarthChief Executive OfficerDec 21Option Exercise1.8115,00027,150148,560Dec 26 05:11 PM
Dylan-Hyde TylerChief Legal OfficerDec 15Sale18.9015,000283,496130,204Dec 19 04:10 PM